This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

William R. Barclay, MD

JAMA. 1981;246(3):252.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

On April 28, 1981, a notice from the Food and Drug Administration published in the Federal Register stayed the effective date of final regulations that would mandate patient package inserts for ampicillin, amoxicillin, hetacillin, cimetidine, clofibrate, phenytoin, and propoxyphene drugs. This stay does not affect requirements for patient package inserts for the oral contraceptive estrogen, and progestational drugs codified earlier in the Federal Register. This stay is welcome, even though it may defer action only until July 1, 1981, for it gives more time to explore the necessity for, and the cost and potential usefulness of, patient package inserts.

Under ideal circumstances, government agencies should not intervene between patient and physician, with mandates concerning diagnosis or treatment. Unfortunately, circumstances are not always ideal; and some patients receive prescriptions from their physician for medications about which the patient has no knowledge and has received no instruction. Some physicians do not put . . . [Full Text PDF of this Article]

Footnotes
Address editorial communications to the Editor, 535 N Dearborn St, Chicago, IL 60610.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?